Literature DB >> 29391280

Injury- and inflammation-driven skin fibrosis: The paradigm of epidermolysis bullosa.

Alexander Nyström1, Leena Bruckner-Tuderman2.   

Abstract

Genetic or acquired destabilization of the dermal extracellular matrix evokes injury- and inflammation-driven progressive soft tissue fibrosis. Dystrophic epidermolysis bullosa (DEB), a heritable human skin fragility disorder, is a paradigmatic disease to investigate these processes. Studies of DEB have generated abundant new information on cellular and molecular mechanisms at play in skin fibrosis which are not only limited to intractable diseases, but also applicable to some of the most common acquired conditions. Here, we discuss recent advances in understanding the biological and mechanical mechanisms driving the dermal fibrosis in DEB. Much of this progress is owed to the implementation of cell and tissue omics studies, which we pay special attention to. Based on the novel findings and increased understanding of the disease mechanisms in DEB, translational aspects and future therapeutic perspectives are emerging.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bacteria; Dystrophic epidermolysis bullosa; Molecular therapy; Omics; Squamous cell carcinoma; Stiffness

Mesh:

Substances:

Year:  2018        PMID: 29391280     DOI: 10.1016/j.matbio.2018.01.016

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  14 in total

Review 1.  Notch-ing up knowledge on molecular mechanisms of skin fibrosis: focus on the multifaceted Notch signalling pathway.

Authors:  Angelo Giuseppe Condorelli; May El Hachem; Giovanna Zambruno; Alexander Nystrom; Eleonora Candi; Daniele Castiglia
Journal:  J Biomed Sci       Date:  2021-05-09       Impact factor: 8.410

2.  A functional outside-in signaling network of proteoglycans and matrix molecules regulating autophagy.

Authors:  Thomas Neill; Aastha Kapoor; Christopher Xie; Simone Buraschi; Renato V Iozzo
Journal:  Matrix Biol       Date:  2021-04-07       Impact factor: 10.447

Review 3.  Skin Fragility: Perspectives on Evidence-based Therapies.

Authors:  Leena Bruckner-Tuderman
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

Review 4.  Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020.

Authors:  Cristina Has; Andrew South; Jouni Uitto
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

5.  Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa.

Authors:  Toini Pemmari; Larisa Ivanova; Ulrike May; Prakash Lingasamy; Allan Tobi; Anja Pasternack; Stuart Prince; Olli Ritvos; Shreya Makkapati; Tambet Teesalu; Mitchell S Cairo; Tero A H Järvinen; Yanling Liao
Journal:  Mol Ther       Date:  2020-05-20       Impact factor: 11.454

Review 6.  Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.

Authors:  Angelo Giuseppe Condorelli; Elena Dellambra; Elena Logli; Giovanna Zambruno; Daniele Castiglia
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

Review 7.  A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.

Authors:  Payal M Patel; Virginia A Jones; Christy T Behnam; Giovanni Di Zenzo; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2021-05-17

Review 8.  Epigenetic and metabolic regulation of epidermal homeostasis.

Authors:  Roland N Wagner; Josefina Piñón Hofbauer; Verena Wally; Barbara Kofler; Matthias Schmuth; Laura De Rosa; Michele De Luca; Johann W Bauer
Journal:  Exp Dermatol       Date:  2021-03-10       Impact factor: 3.960

9.  Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.

Authors:  Susan J Robertson; Elizabeth Orrin; Manpreet K Lakhan; Gavin O'Sullivan; Jessie Felton; Alistair Robson; Danielle T Greenblatt; Catina Bernardis; John A McGrath; Anna E Martinez; Jemima E Mellerio
Journal:  Acta Derm Venereol       Date:  2021-08-24       Impact factor: 3.875

10.  Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index.

Authors:  Nicholas H B Schräder; Eva W H Korte; José C Duipmans; Roy E Stewart; Maria C Bolling; André P Wolff
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.